drugset / Trial / NCT05343637
A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This multicenter, open label, Phase 2a study is designed to evaluate the effect of inhaled RT234 delivered in a dose escalation manner on the change in pulmonary vascular resistance (PVR) in subjects with Pulmonary Arterial Hypertension (PAH) undergoing Right heart catheterization (RHC). This study is also known as Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2a (VIPAH-PRN 2a) study
Timeline
- Start
- 2019-07-30
- Primary completion
- 2020-01-17
- Completion
- 2020-01-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vardenafil | Small molecule | 0.2 mg | Inhaled |
| Subject | Vardenafil | Small molecule | 0.6 mg | Inhaled |
| Subject | Vardenafil | Small molecule | 1.2 mg | Inhaled |
| Subject | Vardenafil | Small molecule | 2.4 mg | Inhaled |